Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 3/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 5/20 | 0.36 |
| ▸ | FLT1 | P17948 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30750830 | 0.83 | RAPGEF4 (0.40) | ARKIF11RAPGEF4KDRFLT1 | |
| SCHEMBL20205053 | 0.83 | TAS2R14 (0.49) | ARKIF11RAPGEF4PDK2KDR | |
| SCHEMBL14267822 | 0.83 | AR (0.49) | ARKIF11RAPGEF4PDK2KDR | |
| SCHEMBL10227623 | 0.81 | NR1H4 (0.36) | ARKIF11PDK2HTTLMNA | |
| SCHEMBL8167857 | 0.79 | KIF11 (0.50) | ARKIF11 | |
| SCHEMBL23974249 | 0.79 | CCNE2 (0.43) | KIF11RAPGEF4KDRFLT1HTT | |
| SCHEMBL6535322 | 0.79 | AR (0.50) | ARRAPGEF4KDRFLT1HTT | |
| SCHEMBL11187639 | 0.78 | KIF11 (0.49) | ARKIF11PDK2FFAR4 | |
| SCHEMBL29886486 | 0.78 | NOTUM (0.49) | ARKIF11PDK2HTTLMNA | |
| SCHEMBL23974264 | 0.78 | NOTUM (0.49) | ARKIF11PDK2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-1207874-A4 | METHODS OF TREATING PROLIFERATIVE DISORDERS | BIOMEDICINES INC (US) | 2004-02-11 | — | — | EP | disclosed |
| US-6566395-B1 | Therapy of proliferative disorders, such as cancers, blood vessel disorders and fibrotic disorders by administering N-(3-methyl-4- trifluoromethylphenyl) 2-cyano-2-(cycloalkylcarbonyl)acetamide compounds | BIOMEDICINES, INC. | 2003-05-20 | — | — | US | disclosed |
| EP-1207874-A1 | METHODS OF TREATING PROLIFERATIVE DISORDERS | Biomedicines, Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2000071113-A1 | METHODS OF TREATING PROLIFERATIVE DISORDERS | BIOMEDICINES, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | AR 276/4885KIF11 3932/4885RAPGEF4 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.